ELUVIA Drug-Eluting Vascular Stent System

Watch the Video

Hear Principal Investigator, William Gray, MD review the IMPERIAL Trial Results

IMPERIAL Trial

Objective

Evaluate the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.

 

IMPERIAL Trial Design

Global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication.

  • 465 (RCT) patients across 64 sites
  • 5-year follow-up
  • Primary patency, freedom from TLR, ankle-brachial index (ABI), Rutherford classification and stent fracture rate evaluated

Primary Endpoints:

  • Safety: Major Adverse Events defined as all causes of death through 1 month, Target Limb Major Amputation through 12 months and/or Target Lesion Revascularization (TLR) through 12 months.
  • Efficacy: Assess primary vessel patency* at 12 months post-procedure.

Key Eligibility Criteria

  • Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4.
  • Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA.
  • Degree of stenosis ≥ 70% by visual angiographic assessment.
  • Vessel diameter ≥ 4 and ≤ 6 mm
  • Total lesion length ≥ 30 mm and ≤ 140 mm

Baseline Characteristics

Patient Demographics
Lesion Characteristics
 
Kaplan-Meier Primary Patency Rate: 12-Month Results chart

 

12-Month Primary Patency Results

Eluvia demonstrated a statistically significant difference in primary patency compared to Zilver PTX at 12 months in the IMPERIAL Trial.

 

12-Month Safety Results

  • 95.1% of Eluvia patients were free of Major Adverse Events at 12 months (vs. 91.0% of Zilver PTX patients)
  • Eluvia demonstrated half the target lesion revascularization rate (TLR) of Zilver PTX at 12 months (4.5% vs. 9.0%)

 

Clinically-Driven TLR Rate  |  12 Months<br /><span style="font-size: 13px;">Gray, W. Presented at TCT 2018. TLR = Target Lesion Revascularization.</span>

Patient Outcomes

  • 85.8% of Eluvia patients presented with no or minimal claudication (Rutherford 0-1) at 12 months (vs. 84.5% of Zilver PTX patients)
  • 89.6% of Eluvia patients had improvement by at least 1 Rutherford category compared with baseline without the need for TLR (vs. 83.1% of Zilver PTX patients)
Clinically-Driven TLR Rate  |  12 Months
 
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top